ArticleAmerican journal of translational research2023
Telmisartan combined with calcitriol enhances therapeutic efficacy for diabetic nephropathy while inhibiting inflammation and renal interstitial fibrosis.
Article in American journal of translational research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 citations in OpenAlex.
- Efficacy of Dapagliflozin and Telmisartan Combination Therapy in Reducing Albuminuria and Inflammatory Markers in Diabetic Nephropathy: A Prospective Observational Study.Current vascular pharmacology · 2025Observational
- Autophagy, Pyroptosis and Ferroptosis are Rising Stars in the Pathogenesis of Diabetic Nephropathy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis retrospective study aims to analyze the effect of telmisartan (TEL) combined with calcitriol (CTL) on therapeutic efficacy, inflammatory status, and renal interstitial fibrosis (RIF) in patients with diabetic nephropathy (DN).
methodsFirst, 126 DN patients admitted between September 2019 and September 2022 were selected, of which 66 cases (research group) were treated with TEL + CTL, and 60 cases (control group) were given TEL alone. The therapeutic efficacy, complications (fever, dizziness, headache, nausea and vomiting, and gastrointestinal reactions), inflammatory status (interleukin (IL)-1β, high-sensitivity C-reactive protein (hs-CRP), and tumor necrosis factor (TNF)-α), RIF (transforming growth factor (TGF)-β1, vascular endothelial growth factor (VEGF), and homocysteine (Hcy)), and renal function (blood urea (BUN), serum creatinine (Cr), and microalbuminuria (mAlb)) were compared between the two groups. Finally, a univariate analysis was performed to identify factors leading to poor prognosis (ineffective treatment) in patients.
resultsA statistically higher overall response rate was determined in the research group as compared to the control group (P<0.05). The two groups exhibited equivalent complication rates (P>0.05). Markedly lower post-treatment IL-1β, hs-CRP, TNF-α, TGF-β1, VEGF, Hcy, BUN, Scr, and mAlb were identified in the research group than those in the control group (P<0.05). Moreover, hs-CRP, TNF-α, BUN, and treatment modality were found to be closely associated with poor prognosis in DN patients (P<0.05).
conclusionsTEL + CTL has a good effect on DN and a comparable safety profile to TEL monotherapy. This combination can significantly inhibit inflammation and RIF and improve renal function in DN patients.
Indexed as
Identifiers
38074815PMC10703670W4389801552What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.